European Patent Office Upholds Gilead’s Sofosbuvir Patent
A challenge brought to the European Patent Office that sought to open the door to generic competition to Gilead’s hepatitis C treatment has failed.
You may also be interested in...
NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.
Access to affordable medicines has become a global challenge. A new chapter has been added to the struggle as several EU-based civil society groups join hands to challenge Gillead’s sofosbuvir patent in a bid to increase access to affordable hepatitis C treatment.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”